May 29 Company Quick Takes: Priority Review for Amarin's Vascepa; plus Tuhura-Moffitt Cancer Center deal and more

Priority Review for Vascepa to reduce CV risk
Amarin Corp. plc (NASDAQ:AMRN) gained $1.98 (12%) to $18.99 on Wednesday after FDA accepted and granted Priority Review to an sNDA for Vascepa icosapent ethyl to reduce residual CV risk in patients with statin-managed LDL-C, but persistent elevated triglycerides. The PDUFA date is Sept. 28; Amarin said FDA did not indicate whether it plans to hold an advisory committee meeting for the application (see "Amarin's Vascepa Reduces Total CV Events by 30% in REDUCE-IT").

Tuhura licenses targeted immunotherapy from Moffitt Cancer Center
The Moffitt Cancer Center granted Tuhura Biopharma Inc. (Seattle, Wash.) exclusive rights to develop its bifunctional immunoconjugates, or cancer cell finding agents linked to immune system activators. The partners will develop the immunoconjugates for solid tumors and blood-related cancers, with an initial focus on lung and head and neck cancer. Financial terms were not disclosed...